Results 251 to 260 of about 22,470,337 (287)
Some of the next articles are maybe not open access.
Pathology, 2018
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide, representing approximately 30-40% of all cases in different geographic regions. Patients most often present with a rapidly growing tumour mass in single or multiple, nodal or extranodal sites.
Shaoying, Li +2 more
openaire +2 more sources
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide, representing approximately 30-40% of all cases in different geographic regions. Patients most often present with a rapidly growing tumour mass in single or multiple, nodal or extranodal sites.
Shaoying, Li +2 more
openaire +2 more sources
Everolimus in Diffuse Large B-Cell Lymphomas
Future Oncology, 2015Satisfactory treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is not currently available and novel therapies are needed. mTOR is an intracellular kinase that is part of an aberrantly activated pathway in DLBCL. Preclinical studies in DLBCL cell lines demonstrated that everolimus, an oral selective mTOR inhibitor, induces cell ...
Merli, Michele +4 more
openaire +4 more sources
Diffuse Large B-Cell Lymphomas and Burkitt Lymphoma
Hematology/Oncology Clinics of North America, 2009Diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphoma (BL) account for the majority of aggressive lymphomas in adults and children. DLBCLs exhibit marked biological heterogeneity and variable clinical presentation and clinical course. Conversely, BL is genetically relatively homogeneous but associated with variable clinicopathological features ...
Laurence, de Leval +1 more
openaire +2 more sources
Diffuse large B-cell lymphoma in the older
Critical Reviews in Oncology/Hematology, 2011The incidence of diffuse large B-cell lymphoma (DLCL) in the older is growing to the point of becoming a health priority in the next decades. Prognostic factors and the biology of the tumor are not very different between younger and older populations.
A, Gutiérrez +3 more
openaire +2 more sources
Seminars in Radiation Oncology, 2007
Diffuse large B-cell lymphoma (DLBCL) is one of the most common subtypes of non-Hodgkin lymphoma. It is a heterogeneous disease, and a distinctive subgroup of patients with different treatment outcome can be identified based on clinical and molecular prognostic factors.
openaire +2 more sources
Diffuse large B-cell lymphoma (DLBCL) is one of the most common subtypes of non-Hodgkin lymphoma. It is a heterogeneous disease, and a distinctive subgroup of patients with different treatment outcome can be identified based on clinical and molecular prognostic factors.
openaire +2 more sources
NHL (diffuse large B-cell lymphoma).
BMJ clinical evidence, 2016Non-Hodgkin's lymphoma (NHL) is the sixth most common cancer in the UK; 9443 new cases were diagnosed in the UK in 2002, and it caused 4418 UK deaths in 2003. Incidence rates show distinct geographical variation, with age-standardised incidence rates ranging from 17 per 100,000 in northern America to 4 per 100,000 in south-central Asia. NHL occurs more
Fiona, Kyle, Mark, Hill
openaire +3 more sources
Treatment of diffuse large B-cell lymphomas
memo - Magazine of European Medical Oncology, 2009Diffuse large B-cell lymphoma represent 40% of all lymphoma. The development of dose-dense chemotherapeutic regimens and the application of the monoclonal CD20 antibody rituximab improve the prognosis significantly. Evaluation of clinical risk factors (age, stage, LDH, ECOG performance status, number of extranodal involvement) at initial diagnosis are ...
B, Gleissner, C, Zwick, M, Pfreundschuh
openaire +2 more sources
The Management of an Orbital Diffuse Large B-Cell Lymphoma
Journal of Craniofacial Surgery, 2014The orbit represents a rare site of presentation of non-Hodgkin lymphoma. The diagnosis and management of orbital lymphomas may be challenging because these neoplasms present few specific features.A 69-year-old woman presented with painless swelling of the left lower eyelid of 5 years' duration.
De Stefani A. +2 more
openaire +4 more sources
Prognostic models for diffuse large b‐cell lymphoma
Hematological Oncology, 2000Prognosis of DLCL patients is variable and associated with well-defined risk factors. In the past decade several pretreatment variables have been incorporated into prognostic models to predict the death risk of individual patients. The International Prognostic Index (IPI), developed in an international consensus study, has been one of the most widely ...
A, Conconi +7 more
openaire +2 more sources
Pathogenesis of diffuse large B cell lymphoma
International Journal of Hematology, 2010Substantial additional insight has been obtained in the past decade regarding the pathogenesis of diffuse large B cell lymphoma (DLBCL). Distinct subtypes of DLBCL have been defined by gene expression profiling (GEP) and they differ not only in GE profiles but also in the pattern of genetic abnormalities.
openaire +2 more sources